Not yet recruitingPhase 4

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment Evaluates Whether a 12-week Exercise and Individualized Nutrition Program Can Reduce Muscle and Bone Loss and Improve Strength, Fitness, and Function in Obese Adults on GLP-1

Combatting Muscle Loss in Obese Adult Patients on GLP-1 Medications Through Dietary Counseling and Exercise During Treatment

Lead sponsor

William Marsh Rice University

Assets

GLP-1 / incretin class catch-all / Semaglutide

Listed sites

Recruiting sites

Estimated enrollment

Study population

Obesity / overweight

Eligibility highlights

•BMI ≥30

Primary endpoint

•Lean mass

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07554417

Org study IDIRB-FY2026-226

Timeline

Milestones

Study start2026-04-06estimated

Study first posted2026-04-28actual

Last update posted2026-04-28actual

Primary completion2026-06-29estimated

Study completion2026-08-06estimated

Assets

Investigational agents

GLP-1 / incretin class catch-all Semaglutide

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age40 Years

Maximum age55 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Age between 40 and 55 years

•Body Mass Index (BMI) greater than 30

•Body fat percentage greater than 30% for males and 40% for females

•Android to gynoid fat ratio greater than 1.0

•Currently eligible for GLP-1 therapy

•No diagnosis of Type II diabetes

Exclusion criteria

•Presence of abnormal ECG findings, including arrhythmias or ischemic changes

•Hypertensive response to exercise, defined as systolic blood pressure exceeding 250 mmHg or diastolic pressure exceeding 115 mmHg

•Hypotensive response to exercise, defined as a drop in systolic pressure greater than 10 mmHg with increasing workload

•VO₂ max below 15 ml/kg/min

•Borg Rating of Perceived Exertion (RPE) greater than 19 during submaximal workloads

•Any contraindications to exercise as defined by ACSM guidelines

•Musculoskeletal limitations that prevent safe participation in exercise

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint

Primary/protocol endpoint

Change in Skeletal Muscle Mass

Time frame:Baseline to 12 weeks

Lean mass

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.